| Q64069330 | A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor |
| Q64077978 | A new predictor is comparable to the updated nomogram in predicting the intermediate- and high-risk prostate cancer but outperforms nomogram in reducing the overtreatment for the low-risk Pca |
| Q45276161 | A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland |
| Q37868926 | Active surveillance for low-risk prostate cancer: an update |
| Q37262639 | Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality |
| Q48629051 | Biochemical recurrence after radical prostatectomy: what does it mean? |
| Q45330678 | Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort |
| Q47100168 | Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy. |
| Q91599665 | Caring for Patients With Prostate Cancer Who Are BRCA Positive |
| Q35641491 | Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer |
| Q90447976 | Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases |
| Q87517848 | Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics |
| Q35888211 | Comorbidities, treatment and ensuing survival in men with prostate cancer |
| Q45064053 | Comorbidity and competing risks for mortality in men with prostate cancer. |
| Q26798912 | Concurrent chemoradiation for high-risk prostate cancer |
| Q85005634 | Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system |
| Q89106473 | Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression |
| Q43065076 | Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis |
| Q95482794 | Editorial comment |
| Q37140722 | Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer |
| Q49670684 | Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer |
| Q26853068 | External beam radiotherapy for localized prostate cancer |
| Q39101615 | First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. |
| Q92869796 | Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom |
| Q87458788 | Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy |
| Q82787914 | Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy |
| Q33410858 | Hypermethylation of genes for diagnosis and risk stratification of prostate cancer |
| Q37421927 | Impact of surgical margin status on prostate-cancer-specific mortality |
| Q43533141 | Income inequality and treatment of African American men with high-risk prostate cancer |
| Q48654496 | Is suspicious upstaging on multiparametric magnetic resonance imaging useful in improving the reliability of Prostate Cancer Research International Active Surveillance (PRIAS) criteria? Use of the K-CaP registry. |
| Q57105378 | Landmarks in prostate cancer |
| Q94596990 | Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea |
| Q42632099 | Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. |
| Q35115736 | Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer |
| Q46066104 | Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer |
| Q33495763 | Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P) |
| Q64902379 | Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. |
| Q38640155 | Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy |
| Q91706754 | National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer |
| Q37014814 | Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer |
| Q37494500 | Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience |
| Q43089360 | Oncologic outcomes following radical prostatectomy in the active surveillance era. |
| Q46832308 | Overtreatment of men with low-risk prostate cancer and significant comorbidity |
| Q41905532 | Perineural invasion is an independent predictor of biochemical recurrence of prostate cancer after local treatment: a meta-analysis |
| Q34765952 | Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study |
| Q42326796 | Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study |
| Q37966912 | Prognostic determinants in prostate cancer |
| Q28065062 | Prostate cancer characteristics in the World Trade Center cohort, 2002-2013 |
| Q35439944 | Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. |
| Q38913913 | Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population |
| Q43523307 | Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy |
| Q45996743 | Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system. |
| Q42103015 | Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL. |
| Q46495723 | Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification |
| Q38280317 | Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective |
| Q38278140 | Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer |
| Q24632732 | Risk stratification and early oncologic outcomes following robotic prostatectomy |
| Q51045839 | Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. |
| Q92671258 | Subclassification of pathologically organ-confined (pT2) prostate cancer does not significantly predict postoperative outcomes in Korean males |
| Q39153917 | Surgical method influences specimen margins and biochemical recurrence during radical prostatectomy for high-risk prostate cancer: a systematic review and meta-analysis |
| Q91642438 | The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status |
| Q38593365 | The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). |
| Q64964104 | The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. |
| Q44838919 | The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. |
| Q60302512 | The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis |
| Q38501645 | The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8-10 disease. |
| Q35894629 | The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia |
| Q92726506 | Under Treatment of Prostate Cancer in Rural Locations |
| Q42202406 | Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation |
| Q35846299 | Vegetable and fruit intake after diagnosis and risk of prostate cancer progression |
| Q41020184 | Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer |
| Q33927594 | What are the outcomes of radical prostatectomy for high-risk prostate cancer? |
| Q53175999 | [Localized intermediate- to high-risk prostate cancer]. |